ABSTRACT
Liver Imaging Reporting and Data System (LI-RADS) provides standardized reporting and a common language for the diagnosis of hepatocellular carcinoma (HCC) on liver computed tomography/magnetic resonance imaging. While aiming for high specificity with liver reporting-5 (LR-5), targetoid findings and LR-M criteria contribute to the differential diagnosis of non-HCC malignancies. Ancillary findings can increase diagnostic confidence, especially in ambiguous nodules such as LR-3/LR-4. Although performance limitations exist in small lesions and atypical HCC subtypes, LI-RADS remains an important reference in patient management thanks to its updatable structure and clinical integration.
Keywords:
LI-RADS, hepatocellular carcinoma, computed tomography, magnetic resonance imaging
References
1
Oh JH, Jun DW. The latest global burden of liver cancer: a past and present threat. Clin Mol Hepatol. 2023; 29: 355-7.
2
Amin N, Anwar J, Sulaiman A, Naumova NN, Anwar N. Hepatocellular carcinoma: a comprehensive review. Diseases. 2025; 13: 207.Erratum in: Diseases. 2025; 13: 257.
3
European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018; 69: 182-236. Erratum in: J Hepatol. 2019; 70: 817. Kim TH, Kim SY, Tang A, Lee JM. Comparison of international guidelines for noninvasive diagnosis of hepatocellular carcinoma: 2018 update. Clin Mol Hepatol. 2019; 25: 245-63.
4
American College of Radiology (ACR). LI-RADS®: CT/MRI v2018 Core [Internet]. Reston (VA): American College of Radiology; 2018 [cited 2026 Feb]. Available from:
5
Clarke CGD, Albazaz R, Smith CR, Rowe I, Treanor D, Wyatt JI, et al. Comparison of LI-RADS with other non-invasive liver MRI criteria and radiological opinion for diagnosing hepatocellular carcinoma in cirrhotic livers using gadoxetic acid with histopathological explant correlation. Clin Radiol. 2021; 76: 333-41.
6
Kim YY, Choi JY. CT/MRI Liver Imaging Reporting and Data System (LI-RADS): standardization, evidence, and future direction. J Korean Soc Radiol. 2023; 84: 15-33. Korean.
7
Chernyak V, Fowler KJ, Kamaya A, Kielar AZ, Elsayes KM, Bashir MR, et al. Liver Imaging Reporting and Data System (LI-RADS) version 2018: imaging of hepatocellular carcinoma in at-risk patients. Radiology. 2018; 289: 816-30.
8
Choi SH, Fowler KJ, Chernyak V, Sirlin CB. LI-RADS: current status and future directions. Korean J Radiol. 2024; 25: 1039-46.
9
Elsayes KM, Kielar AZ, Chernyak V, Morshid A, Furlan A, Masch WR, et al. LI-RADS: a conceptual and historical review from its beginning to its recent integration into AASLD clinical practice guidance. J Hepatocell Carcinoma. 2019; 6: 49-69.
10
Lee S, Kim YY, Shin J, Hwang SH, Roh YH, Chung YE, et al. CT and MRI Liver Imaging Reporting and Data System Version 2018 for hepatocellular carcinoma: a systematic review with meta-analysis. J Am Coll Radiol. 2020; 17: 1199-206.
11
Jha RC, Mitchell DG, Weinreb JC, Santillan CS, Yeh BM, Francois R, et al. LI-RADS categorization of benign and likely benign findings in patients at risk of hepatocellular carcinoma: a pictorial atlas. AJR Am J Roentgenol. 2014; 203: W48-69.
12
Chen X, Cai Q, Xia J, Huang H, Li Z, Song K, et al. Liver Imaging Reporting and Data System (LI-RADS) v2018: differential diagnostic value of ADC values for benign and malignant nodules with moderate probability (LR-3). Front Oncol. 2023; 13: 1186290.
13
Elsayes KM, Hooker JC, Agrons MM, Kielar AZ, Tang A, Fowler KJ, et al. 2017 version of LI-RADS for CT and MR imaging: an update. Radiographics. 2017; 37: 1994-2017.
14
Choi JY, Lee JM, Sirlin CB. CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part II. extracellular agents, hepatobiliary agents, and ancillary imaging features. Radiology. 2014; 273: 30-50.
15
Kielar AZ, Elsayes KM, Chernyak V, Tang A, Sirlin CB. LI-RADS version 2018: what is new and what does this mean to my radiology reports? Abdom Radiol (NY). 2019; 44: 41-2.
16
Chernyak V, Tang A, Flusberg M, Papadatos D, Bijan B, Kono Y, et al. LI-RADS ® ancillary features on CT and MRI. Abdom Radiol (NY). 2018; 43: 82-100.
17
Kielar A, Fowler KJ, Lewis S, Yaghmai V, Miller FH, Yarmohammadi H, et al. Locoregional therapies for hepatocellular carcinoma and the new LI-RADS treatment response algorithm. Abdom Radiol (NY). 2018; 43: 218-30.
18
Becker-Weidman D, Civan JM, Deshmukh SP, Roth CG, Herrine SK, Parker L, et al. Hepatocellular carcinoma after locoregional therapy: magnetic resonance imaging findings in falsely negative exams. World J Hepatol. 2016; 8: 685-90.
19
Yoneda N, Matsui O, Kitao A, Kozaka K, Kobayashi S, Sasaki M, et al. Benign hepatocellular nodules: hepatobiliary phase of gadoxetic acid-enhanced MR imaging based on molecular background. Radiographics. 2016; 36: 2010-27.
20
Mamone G, Miraglia R. The “peripheral wash-out sign” in hepatic malignant lesions. Abdominal Radiology. 2019; 44: 2937-2938.
21
Prasad SR, Wang H, Rosas H, Menias CO, Narra VR, Middleton WD, et al. Fat-containing lesions of the liver: radiologic-pathologic correlation. Radiographics. 2005; 25: 321-31.
22
Yu SC, Yeung DT, So NM. Imaging features of hepatocellular carcinoma. Clin Radiol. 2004; 59: 145-56.
23
Min JH, Lee MW, Park HS, Lee DH, Park HJ, Lee JE, Park SJ, et al. LI-RADS version 2018 targetoid appearances on gadoxetic acid-enhanced MRI: interobserver agreement and diagnostic performance for the differentiation of HCC and non-HCC malignancy. AJR Am J Roentgenol. 2022; 219: 421-32.
24
Lee HS, Kim MJ, An C. How to utilize LR-M features of the LI-RADS to improve the diagnosis of combined hepatocellular-cholangiocarcinoma on gadoxetate-enhanced MRI? Eur Radiol. 2019; 29: 2408-16.
25
Rhee H, Park JH, Park YN. Update on pathologic and radiologic diagnosis of combined hepatocellular-cholangiocarcinoma. J Liver Cancer. 2021; 21: 12-24.
26
Kim DH, Choi SH. Inter-reader agreement for CT/MRI LI-RADS category M imaging features: a systematic review and meta-analysis. J Liver Cancer. 2024; 24: 192-205.
27
Low G, Pfanner T, Qian XJ, Ramji A, Samji K, Wilson MP. LR-M for CT/MRI on LI-RADS v2018: a review of imaging criteria, performance, challenges and future directions from an end-user perspective. Abdominal Radiology. 2025; 1-15.
28
Kim SH, Lim HK, Lee WJ, Choi D, Park CK. Scirrhous hepatocellular carcinoma: comparison with usual hepatocellular carcinoma based on CT-pathologic features and long-term results after curative resection. Eur J Radiol. 2009; 69: 123-30.
29
Choi SY, Kim SH, Park CK, Min JH, Lee JE, Choi YH, et al. Imaging features of gadoxetic acid-enhanced and diffusion-weighted MR imaging for identifying cytokeratin 19-positive hepatocellular carcinoma: a retrospective observational study. Radiology. 2018; 286: 897-908.
30
Cerny M, Chernyak V, Olivié D, Billiard JS, Murphy-Lavallée J, Kielar AZ, et al. LI-RADS version 2018 ancillary features at MRI. Radiographics. 2018; 38: 1973-2001.
31
Cannella R, Vernuccio F, Sagreiya H, Choudhury KR, Iranpour N, Marin D, et al. Liver Imaging Reporting and Data System (LI-RADS) v2018: diagnostic value of ancillary features favoring malignancy in hypervascular observations ≥ 10 mm at intermediate (LR-3) and high probability (LR-4) for hepatocellular carcinoma. Eur Radiol. 2020; 30: 3770-81.
32
Jeon SK, Joo I, Bae JS, Park SJ, Lee JM. LI-RADS v2018: how to appropriately use ancillary features in category adjustment from intermediate probability of malignancy (LR-3) to probably HCC (LR-4) on gadoxetic acid-enhanced MRI. Eur Radiol. 2022; 32: 46-55.
33
van der Pol CB, Dhindsa K, Shergill R, Zha N, Ferri M, Kagoma YK, et al. MRI LI-RADS version 2018: impact of and reduction in ancillary features. AJR Am J Roentgenol. 2021; 216: 935-42.
34
Kim DH, Choi SH, Park SH, Kim KW, Byun JH, Kim SY, et al. Meta-analysis of the accuracy of Liver Imaging Reporting and Data System category 4 or 5 for diagnosing hepatocellular carcinoma. Gut. 2019; 68: 1719-21.
35
van der Pol CB, Lim CS, Sirlin CB, McGrath TA, Salameh JP, Bashir MR, et al. Accuracy of the Liver Imaging Reporting and Data System in computed tomography and magnetic resonance image analysis of hepatocellular carcinoma or overall malignancy-a systematic review. Gastroenterology. 2019; 156: 976-86.
36
Cerny M, Bergeron C, Billiard JS, Murphy-Lavallée J, Olivié D, Bérubé J, et al. LI-RADS for MR imaging diagnosis of hepatocellular carcinoma: performance of major and ancillary features. Radiology. 2018; 288: 118-28.
37
Fowler KJ, Tang A, Santillan C, Bhargavan-Chatfield M, Heiken J, Jha RC, et al. Interreader reliability of LI-RADS version 2014 algorithm and imaging features for diagnosis of hepatocellular carcinoma: a large international multireader study. Radiology. 2018; 286: 173-85.
38
Hope TA, Aslam R, Weinstein S, Yeh BM, Corvera CU, Monto A, et al. Change in Liver Imaging Reporting and Data System characterization of focal liver lesions using gadoxetate disodium magnetic resonance imaging compared with contrast-enhanced computed tomography. J Comput Assist Tomogr. 2017; 41: 376-81.
39
Zhang YD, Zhu FP, Xu X, Wang Q, Wu CJ, Liu XS, et al. Liver Imaging Reporting and Data System:: substantial discordance between CT and MR for imaging classification of hepatic nodules. Acad Radiol. 2016; 23: 344-52.
40
Liang Y, Xu F, Guo Y, Lai L, Jiang X, Wei X, et al. Diagnostic performance of LI-RADS for MRI and CT detection of HCC: a systematic review and diagnostic meta-analysis. Eur J Radiol. 2021; 134: 109404.
41
Kim YY, Kim MJ, Kim EH, Roh YH, An C. Hepatocellular carcinoma versus other hepatic malignancy in cirrhosis: performance of LI-RADS version 2018. Radiology. 2019; 291: 72-80.
42
Choi SH, Lee SS, Park SH, Kim KM, Yu E, Park Y, et al. LI-RADS Classification and prognosis of primary liver cancers at gadoxetic acid-enhanced MRI. Radiology. 2019; 290: 388-97.
43
Jeon SK, Joo I, Lee DH, Lee SM, Kang HJ, Lee KB, et al. Combined hepatocellular cholangiocarcinoma: LI-RADS v2017 categorisation for differential diagnosis and prognostication on gadoxetic acid-enhanced MR imaging. Eur Radiol. 2019; 29: 373-82.
44
Joo I, Lee JM, Lee DH, Jeon JH, Han JK, Choi BI. Noninvasive diagnosis of hepatocellular carcinoma on gadoxetic acid-enhanced MRI: can hypointensity on the hepatobiliary phase be used as an alternative to washout? Eur Radiol. 2015; 25: 2859-68.
45
Kim DH, Choi SH, Kim SY, Kim MJ, Lee SS, Byun JH. Gadoxetic acid-enhanced MRI of hepatocellular carcinoma: value of washout in transitional and hepatobiliary phases. Radiology. 2019; 291: 651-7.. Erratum in: Radiology. 2019; 292: 270.
46
Kim DH, Choi SH, Park SH, Kim KW, Byun JH, Kim SY, et al. Liver imaging reporting and data system category M: a systematic review and meta-analysis. Liver Int. 2020; 40: 1477-87.
47
Min JH, Kim YK, Choi SY, Jeong WK, Lee WJ, Ha SY, et al. Differentiation between cholangiocarcinoma and hepatocellular carcinoma with target sign on diffusion-weighted imaging and hepatobiliary phase gadoxetic acid-enhanced MR imaging: classification tree analysis applying capsule and septum. Eur J Radiol. 2017; 92: 1-10.
